Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3608_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
29.08.2026
Размер:
83 Мб
Скачать
% Prevalence
Rotterdam study
60
(Meijer, 1998)
213
FIGURE 161 Peripheral artery disease (PAD) prevalence. Estimates based on ankle-
brachial index (ABI) from six large studies.
50
40
30
20
10
0
40 50 60 70 80 90
Age
Hoorn study, men (Beks, 1995)
Hoorn study, women (Beks, 1995)
San Diego population study (Criqui, 1985)
Limburg study, men (Stoffers, 1996)
Limburg study, women (Stoffers, 1996)
Cardiovascular health study, ex CVD, men (Newman, 1993)
Cardiovascular health study, ex CVD, women (Newman, 1993)
Honolulu heart program, men only, (Curb, 1996)
CH 16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
estimates in men and women were similar by age 65 to 74. In a group of Israeli men, incidence of claudication ranged from 6.3 per 1000 per year at ages 40 to 49 to 10.5 per 1000 at age 60 and greater. dence rose from 0.7 per 1000 per year at ages 35 to 44, to 3 per 1000 per year at ages 45 to 54, 7 per 1000 per year at ages 55 to 63, and 9 per 1000 at age 65 and greater. followed English men aged 45 to 63 years for 10 years, claudica­tion incidence per 1000 per year ranged from 3.1 in the youngest to 4.9 in the oldest age group, based on age at baseline examina­tion. among men and women aged 55 to 74 in the Edinburgh Artery Study; however, this study did not apply strict Rose criteria for probable claudication.
techniques to conclude that intermittent claudication rates among Icelandic men dropped significantly between 1968 and 1986. Among 50-year-old men, their estimate of the rate of claudication dropped from 1.7 per 1000 per year in 1970 to 0.6 per 1000 per year in 1984, whereas in 70-year olds, the rate of claudication dropped from 6.0 to 2.0. smoking and cholesterol levels. The design and duration of this study were uniquely suited to estimating long-term trends in disease incidence; comparable studies for other populations are unavailable. The potential for trends of this magnitude should be considered in reviewing results of other studies. Figure 16-2 shows incidence rates by age for various studies identifying PAD based on claudication.
time and resources required to periodically retest study subjects for incident disease. In the Limburg PAOD Study, incidence rates for PAD were based on two ABI measurements of less than 0.95. Among men, annual incidence was 1.7 per 1000 at ages 40 to 54; 1.5 per 1000 at ages 55 to 64; and 17.8 per 1000 at ages 65 and greater.
1
In a study of 4570 men from Quebec, claudication inci-
38
In the Speedwell Study that
39
A higher incidence of 15.5 per 1000 per year was reported
40
In the Reykjavik Study, Ingolfsson et al. used Poisson regression
41
The authors attributed this to decreased
1,37–39,41
There are very few ABI-based studies of PAD incidence, given the
Annual incidence in women was higher: 5.9, 9.1, and 22.9 per 1000, respectively, for the same age groups.
42
Sex differences in incidence and prevalence of PAD are less
clear than those in other cardiovascular diseases.
Claudication incidence and prevalence have usually been found to be higher in men than women. For example, in the Framingham Study, annual claudication incidence for all ages combined was 7.1 per 1000 in men versus 3.6 per 1000 in women, for a male-to-female ratio of 1.97.
37
In the Framingham Offspring Study, claudication prevalence was 1.9% in men versus 0.8% in women (ratio = 2.38), whereas in the Rotterdam Study it was
2.2% in men versus 1.2% in women (ratio = 1.83).
10,30
However, the Edinburgh Artery Study and the Limburg PAOD Study found much lower male-to-female ratios of claudication prevalence of 1.11 and
1.2, respectively.
23,35
The case for an excess of disease among males is even weaker for PAD diagnosed based on ABI. This is true even in those studies find­ing a clear male excess with respect to claudication. For example, in the Framingham Offspring Study mentioned earlier, PAD based on ABI was found in 3.9% of men and 3.3% of women, for a ratio
30
of 1.18. in men than in women, with prevalences of 16.9% and 20.5% for a ratio of 0.82
In the Rotterdam Study, ABI-based PAD was actually lower
10.
The Limburg PAOD Study, which reported a low male-to-female ratio for claudication, reported a similarly low ratio of 1.1 for ABI-based PAD.35 A population-based study from Southern Italy found prevalences of PAD based on ABI of less than 0.9 to be very similar in men and women, with male to female ratios by age of .89 to .99.
43
In the CHS, ABI of less than 0.9 was somewhat more prevalent in men than women (13.8% vs. 11.4%; ratio = 1.21), but the association of disease with sex was not significant after adjustment for age and cardiovascular disease status.
15
In the Atherosclerosis Risk in Communities (ARIC) Study, PAD prevalence based on ABI was actually lower in men than women among both African Americans (3.3% vs. 4.0%) and whites (2.3% vs. 3.3%).
44
214
Annual incidence per 1000
12
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
CH
16
10
8
6
4
2
0
40 50 60 70 80 90
Age
Framingham men (Kannel, 1985)
Framingham women (Kannel, 1985)
Israeli men (Bowlin, 1994)
Quebec men (Dagenais, 1991)
Speedwell men (Bainton, 1994)
Reykjavik men 1984 (Ingolfsson, 1994)
Reykjavik men 1970 (Ingolfsson, 1994)
FIGURE 162 Peripheral arte ry diseas e (PAD) incidence. Estimates based on
claudication from five large studies.
The greater male excess observed for symptomatic versus ABI-diagnosed disease may be related to severity of disease. A prevalence study in Southern California found that the excess of disease among males increased with severity of PAD.33 A report from the Multi-Ethnic Study of Atherosclerosis (MESA) showed PAD prevalence (ABI of less than 0.90) was the same in men and women (3.7%), but borderline values of ABI (0.90-0.99) were much higher in women (10.6% vs. 4.3%).
Peripheral Artery Disease Risk Factors
The section that follows reviews existing evidence for the asso­ciation of various possible risk factors with PAD. It begins with a discussion of traditional risk factors long implicated in athero­sclerotic processes underlying coronary heart and cerebrovas­cular disease, and then moves on to a discussion of emerging or “novel” risk factors. Where applicable, information on interaction between risk factors and the impact of risk factors on the natural history of disease are also provided.
The study of PAD epidemiology raises a number of methodologi­cal issues that should be kept in mind while reviewing the literature. As discussed earlier, the definition of disease has evolved over time, with earlier studies focusing more on claudication as measured using Rose and other criteria, and later studies using the ABI with a value of 0.9 or less, now widely used to define disease. These different potential definitions are noted throughout.
Methodologically, the strongest epidemiological evidence for a causal relationship between disease and putative risk fac­tors comes from studies of incident disease. Such studies usually involve measurement of risk factors at a baseline examination, with subsequent tracking of incident disease among the subjects. Acute events such as myocardial infarction (MI) and stroke lend themselves to such study because the date of onset of disease is generally documented in the records of healthcare providers and recalled by subjects. Conversely, the onset of PAD as defined by ABI is often asymptomatic, and in any case is unlikely to be docu­mented other than through periodic reexamination of all the sub­jects, which involves substantial time and expense. For that reason, many studies of PAD risk factors are based on cross-sectional asso­ciations; that is, the association between current disease status and current risk factor measurements. Although such studies are poten­tially informative, reported associations cannot conclusively prove causation because it is not known whether the risk factor preceded the disease or vice versa. Caution should therefore be exercised in reviewing results of such cross-sectional studies, particularly where reverse causation is plausible. For example, low physical activity
might cause claudication, but claudication might just as plausibly cause low physical activity.
It is necessary to adjust for multiple potential risk factors in a single statistical model to accurately estimate the unique contribution of any single risk factor because the potential risk factors for PAD are themselves interrelated in various ways. Estimates presented
45
subsequently are based on such multiple adjustment for all traditional PAD risk factors except as noted. Null findings may indicate lack of a real association but may also be based on insuffi­cient sample size. Most of the null findings discussed are based on failure of the risk factor of interest to remain statistically significant in stepwise regression models, which vary as to their algorithms for variable selection.
The following discussion of risk factors focuses on the results from five large epidemiological studies referred to as index studies (
Table 16-2). These studies each had over 3000 subjects drawn from
the general population and included both men and women. The studies are similar enough in their selection and manner of measur­ing risk factors and in their statistical analyses to allow reasonable comparisons for most of the common risk factors. Although the discussion draws on data from many other studies (see
Table 16-2
for a partial list), data are presented from these five studies across all the conventional cardiovascular disease risk factors to provide some consistency and comparability for the reader, and as a check against potential biases that might be introduced by selecting all the studies to present for each risk factor in a more ad hoc fashion.
Smoking
Smoking is one of the strongest risk factors for PAD in virtually all studies. Studies vary as to their measurement of smoking, often com­bining a categorical assessment of smoking status (current, past, or never) with some measure of current or historical volume of smok­ing; these multiple approaches to measurement make comparisons difficult. However, even with some type of additional adjustment for volume of smoking, current smoking versus nonsmoking has been shown to at least double the odds of PAD in most studies, with some estimates as high as a four times greater risk among smokers than others. Among the index studies, current smoking (vs. never or for­mer/never) resulted in 2.0 to 3.4 times higher odds of PAD in the three studies using such categorization; however, in two of these studies, the models also included pack-years of smoking as a signifi­cant variable. The Rotterdam study included only current packs/day, showing a doubling of the odds of PAD for each pack a day smoked (
Table 16-3). All the large population-based studies reviewed found
a significant independent association between PAD and smoking.
TABLE 16-2 Population-Based Studies of Peripheral Artery Disease
STUDY NAME
Index Studies
Framingham Study Murabito, 1997 5209 United States Cross-sectional IC Framingham Offspring Study Murabito, 2002 3313 United States Longitudinal ABI < 0.9 Cardiovascular Health Study Newman, 1993 5084 United States Ages 65+ Cross-sectional ABI < 0.9 Rotterdam Study Meijer, 2000 6450 Netherlands Cross-sectional ABI < 0.9 (<.7 also studied) Multi-Ethnic Study of
Atherosclerosis
Other Large Studies
Honolulu Heart Program Curb, 1996 3450 United States Japanese American
Edinburgh Artery Study Fowkes, 1992 1592 Scotland Cross-sectional ABI and reactive hyperemia Limburg PAOD Study Hooi, 2001 2327 Netherlands Longitudinal ABI < 0.95 Israeli Ischemic Heart Disease Bowlin, 1994 10,059 Israel Middle-aged men Longitudinal IC projected Reykjavik Study Ingolfsson, 1994 9141 Iceland Men only Longitudinal IC Quebec Cardiovascular Study Dagenais, 1991 4570 Canada Men only Longitudinal IC Physicians’ Health Study Ridker, 2001 14,916 United States Male physicians Nested case-control IC or PAD surgery San Diego Population Study Criqui, 2005 2343 United States Multiethnic Cross-sectional ABI 0.9, abnormal
*
Where multiple papers were published, this refers to the paper most frequently referenced herein.
ABI, ankle-brachial index; IC, intermittent claudication, PAD, peripheral artery disease.
FIRST AUTHOR,
YEAR*
Allison, 2006 6653 United States Cross-sectional ABI 0.9
NO. OF
SUBJECTS COUNTRY
POPULATION
CHARACTERISTICS STUDY DESIGN
men
Cross-sectional and
longitudinal
PAD ENDPOINT
ABI < 0.9
waveform, PAD revascularization
TABLE 16-3 Smoking as a Peripheral Artery Disease Risk Factor
95% CI
STUDY VARIABLE ODDS RATIO LOW HIGH
Framingham Study Current packs/day 1.96 1.69 2.25
Framingham Offspring Study Current smoker (vs. former or never) 2.00 1.10 3.40
Pack-years of smoking 1.03 1.02 1.03
Cardiovascular Health Study Current smoker (vs. former or never) 2.55 1.76 3.68
Pack-years of smoking 1.01 1.01 1.02
Rotterdam Study Current smoker (vs. never) 2.69 1.67 4.33
Former smoker (vs. never) 1.15 0.75 1.78
Multi-Ethnic Study of Atherosclerosis Current smoker (vs. never) 3.42 2.48 4.73
215
CH 16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
Cessation of smoking among patients with claudication has been shown to improve various functional and physiological mea­sures related to PAD, as well as reducing mortality.
46–48
However, because symptomatic PAD patients have long been advised to quit smoking, it is possible that observational comparisons of patients who quit smoking with those who do not are confounded by other differences in compliance with medical advice between the two groups. Randomized trials of this question would raise ethical issues, but substantial bias is unlikely, given the large effect size for cigarette smoking.
Aside from the large increase in risk associated with it, smoking is the traditional risk factor for which the best case can be made for a more important role in PAD than in other atherosclerotic diseases. In a comparison of risk factors conducted in the same large cohort, Fowkes et al. found smoking to be associated with a significantly higher relative risk for PAD compared to other cardiovascular diseases. Smoking was the only traditional cardiovascular disease risk factor for which the odds ratio differed signi ficantly between PAD and other cardiovascular diseases.
49
Diabetes
Diabetes is strongly associated with an elevated risk of PAD, although the evidence for an independent role in multivariable analysis is not entirely consistent. Four of the five index studies found diabetes, dichotomized based on different criteria, to be associated with PAD after multivariable adjustment, with odds
ratios ranging from 1.89 to 4.05. Study found such an association on an age- and sex-adjusted basis, but not in multivariable models.
9,15,50,51
The Framingham Offspring
30
Among other large population-based studies, multivariable logis­tic regression models have often shown a relationship to diabetes as a categorical variable, as linear variables. sugar measures were seen in the Edinburgh Artery Study Reykjavik Study.
41
1,34,36,42,52
39
Other null findings for diabetes or blood
or various blood sugar measures
49
and the
More severe and/or long-standing diabetes appears to be more strongly related to PAD. In the Hoorn Study, it was shown that known diabetes was associated with PAD in multivariable analysis, whereas newly diagnosed diabetes was only of borderline significance, and impaired glucose tolerance was not associated with PAD.34 In that study, after excluding known diabetics, none of the common glyce­mic indices that were tested were significantly associated with PAD bas ed on ABI, although significant associations were observed when the PAD criteria were broadened to include patients with additional criteria. Studies conducted in patients with diabetes have shown that duration of diabetes and use of insulin are associated with PAD.
53–55
Outcomes of PAD in diabetic patients have been shown to be worse. In one study, diabetic patients with PAD were five times more likely to have an amputation than other PAD patients; they also had more than three times the odds of mortality.
56
There is also some evidence to support a somewhat different anatomical distri­bution of disease, with more disease in arteries distal to the knee in diabetic than nondiabetic persons.
56,57
216
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Lipids
As is the case in cardiovascular disease epidemiology, the chal­lenge of defining the roles of various lipid fractions in PAD lies in identifying the strongest independent risk factors from among multiple correlated measures. In recent studies, recognition that
CH
the ratio of total cholesterol to high-density lipoprotein (HDL)
16
cholesterol is the best lipid measure of risk,58 along with increasing use of medication, has led to analyses that employ both these vari­ables in the same model in a single variable (e.g., “dyslipidemia”). studies appear in
Total cholesterol was the first lipid measure examined as a potential risk factor for PAD and has been the most widely studied. Total cholesterol was examined as a potential risk factor in four of the index studies, and was significantly associated with PAD in multivariable analysis in three. In the remaining study, total cholesterol was significant in univariate analysis but dropped out of multivariable models that considered other lipid mea-
30
sures.
Similarly, in other studies total cholesterol has usually been found to be associated with PAD, null findings in multivariable analyses where other lipid measures are considered. terol as the sole lipid measure was an analysis of the Quebec Cardiovascular Study cohort.
High-density lipoprotein cholesterol (HDL-C) has been shown to be protective against PAD in most studies where it was evalu­ated, usually in models that also considered total cholesterol. High-density lipoprotein cholesterol was included among poten­tial risk factors in three of the five index studies and in the TC/ HDL-C ratio in a fourth, and was significantly associated with PAD in multivariable analysis in all four. In two studies, both HDL-C and total cholesterol were significant in multivariable analysis, whereas in one study HDL-C but not total cholesterol was significant. Other studies have also shown a protective effect of HDL-C.
Bowlin et al. found that non-HDL cholesterol (total cholesterol minus HDL cholesterol) was significantly associated with incident claudication in a large cohort of Israeli men. Neither total cho­lesterol nor HDL cholesterol were significantly associated with disease in models that included non-HDL cholesterol. parison of incident cases of claudication with healthy controls in the Physician's Health Study, Ridker et al. found that the ratio of total to HDL cholesterol was the lipid measure most strongly associated with disease, with patients in the highest quartile hav­ing 3.9 times the claudication risk of patients in the lowest quartile. Screening for other lipid fractions was judged to have little clinical usefulness beyond measurement of this ratio.
Evidence for high triglycerides as an independent risk factor for PAD is fragmentary. Early case-control studies showed a very con­sistent relationship between triglycerides and PAD, suggesting a uniquely strong relationship with PAD, but large population-based
52
or combine the ratio with medication use
51
Results from the index
Table 16-4.
1,36,41,49
with occasional
39,59
One of the few null findings for total choles-
38
36,59
60
1
In a com-
cohort studies employing multivariable modeling later called this into question.
49,61
Among the index studies, only two included tri­glycerides among the potential risk factors evaluated. In both cases, triglycerides were significant in univariate analysis but dropped out of multivariable models based on stepwise logistic regression.
15,30
Similarly, in the Edinburgh Artery Study cohort and in a large study of geriatric patients in the United States, triglycerides were not significantly associated with PAD after adjustment for other lipid meaures. significantly and independently associated with PAD in multivari­able analysis. vated triglycerides may have a special role in disease progression or more severe PAD.
49,59
However, other studies have shown triglycerides to be
39,53,62
There is also some evidence suggesting that ele-
49,63
In summary, although total cholesterol, HDL-C, and triglycerides all appear to be associated with PAD on a univariate basis, in mul­tivariable analysis triglycerides frequently drop out as an indepen­dent risk factor. Although it has been the most extensively studied, it is not clear that total cholesterol is the strongest independent risk factor for PAD; in one comparison of PAD patients with healthy con­trols, it was found that mean total cholesterol did not differ signifi­cantly, whereas triglycerides, very low-density lipoprotein (VLDL) cholesterol, low-density lipoprotein (LDL) cholesterol, HDL choles­terol, and the total-to-HDL cholesterol ratio all did.
64
Total and HDL cholesterol seem to provide distinct informa­tion and lend themselves to summarization in a single ratio. Because many early studies considered only total cholesterol, full resolution of the question of which lipid measures are most strongly and independently related to PAD awaits completion of additional large-scale studies that assess all relevant lipid risk factors. Irrespective of results from multivariable analysis, simple descriptive statistics and clinical observation both suggest that PAD patients are frequently diabetic or insulin resistant, with the typical dyslipidemia of insulin resistance (i.e., low HDL and high triglycerides).
Hypertension and Blood Pressure
The association of hypertension with PAD has been demonstrated in most studies in which blood pressure was studied. All five of the index studies reported a significant association between hyperten­sion as a categorical variable and PAD. The lowest reported odds ratio was 1.32 as reported in the Rotterdam Study; this is some­what understated relative to the others, since it was based on a model that included both a categorical hypertension variable and an adjustment for systolic blood pressure level that was also sig­nificant.
1.50 to 2.20. Most other large population-based studies have also found a significant independent association of hypertension or systolic blood pressures with PAD.
systolic pressure was usually found to be associated with PAD,
9
Other than this, odds ratios for hypertension ranged from
38,39,42,49,52
Where both systolic and diastolic pressures were considered,
TABLE 16-4 Lipid Measures as Peripheral Artery Disease Risk Factors
95% CI
STUDY VARIABLE ODDS RATIO LOW HIGH
Framingham Study*
Framingham Offspring Study
Cardiovascular Health Study
Rotterdam Study
Multi-Ethnic Study of Atherosclerosis
*
Only total cholesterol was tested.
Hypercholesterolemia (240 mg/dL or medication) and triglycerides dropped out of stepwise logistic regression model.
Triglycerides dropped out of stepwise logistic regression model.
§
Triglycerides not tested.
||
Total/HDL cholesterol ratio > 5.0 or lipid medication use.
HDL, high-density lipoprotein.
§
||
Total cholesterol (10 mg/dL) 1.05 1.02 1.07
HDL cholesterol (5 mg/dL) 0.90 0.80 1.00
Total cholesterol (10 mg/dL) 1.10 1.06 1.14 HDL cholesterol (5 mg/dL) 0.95 0.90 1.00
Total cholesterol (10 mg/dL) 1.05 1.01 1.08 HDL cholesterol (5 mg/dL) 0.93 0.87 1.00
Dyslipidemia (yes/no) 1.58 1.22 2.05
whereas diastolic pressure was not significantly associated or had a nonlinear relationship with PAD.
36
Two large studies
9,15,65
found no relationship of blood pressure with PAD. In the Israeli Ischemic Heart Disease Project cohort, neither systolic nor dia­stolic blood pressure was associated with claudication,
1
whereas in the Reykjavik Study, systolic and diastolic blood pressures were significantly associated with claudication in cross-sectional but not longitudinal models.41 It is interesting to note that both of these studies appear to have used blood pressure as a linear term in their models. Most other recent large studies have used a cate­gorization of subjects into normotensive and hypertensive groups based on systolic and diastolic pressures as well as hypertension medication use.
Both of the null findings also come from studies in which clau­dication was the outcome of interest. It has been speculated that elevated central perfusion pressure as indicated by (axial) blood pressure will sometimes delay onset of claudication by increasing blood pressure in the lower extremities, which—if true—would obscure the relationship of hypertension with underlying disease processes.
66
However, randomized trials of blood pressure lower-
ing in PAD patients generally do not report worsened claudication.
Although the relative risks associated with hypertension are mod­est in some studies, its high prevalence, particularly among older patients, make it a significant contributor to the total burden of PAD in the population. For example, in one large study from the Netherlands, the odds ratio for hypertension was 1.32, but its attributable risk (a measure of the proportion of PAD due to hypertension in the popula­tion) was 17.0%, second only to current smoking in this group. Framingham Study, 30% of the risk of claudication in the population was attributable to blood pressure in excess of 160/100.
9
In the
50
Obesity
1.46) for incident claudication related to a 5.0 kg/m2 difference in body mass index (BMI) in a study of 10,059 Israeli men.
Three of the index studies and a number of other large popu­lation-based studies have failed to find a significant association between obesity and PAD or claudication after multivariable adjust-
9,30,41,42,51,59
ment.
There have also been many studies, including the other two index studies, in which higher relative weight or BMI was actually shown to be protective against PAD. In the Framingham Study, claudication was significantly inversely related to relative weight in men in multivariable analysis, and appeared to have a “U-shaped” nonlinear relationship with relative weight in women. In an analysis from the Edinburgh Artery Study, BMI was signifi­cantly associated with less disease in preliminary multivariable analysis, although BMI was excluded from the paper's final multi­variable model because it “suggested a counterintuitive effect.” The CHS found higher BMI to be significantly protective against PAD after multivariable adjustment in a large sample of Medicare benefi-
15
ciaries. (defined based on a combination of ABI, Doppler flow curves, and history of surgery) in the Hoorn Study.
Body mass index was significantly protective against PAD
34
Similarly, the odds of PAD among subjects in the highest quintile of BMI compared with the lowest quintile were found to be significantly reduced in a cross­sectional analysis of elderly Japanese American men. with higher BMI were again shown to be at significantly lower risk of PAD in a study of Taiwanese subjects with diabetes. multiethnic San Diego Population Study (SDPS) reported a signifi­cant inverse association for BMI and PAD.
52
Obesity has been implicated in the etiology of other risk fac­tors for PAD, such as hypertension, type II diabetes, and dyslipid­emia. In epidemiology, adjusting for factors that are on the causal pathway between a risk factor and disease is known to attenuate the observed strength of that risk factor. Therefore, estimates of risks related to obesity in multivariable models are estimates of the risk
1
36
Subjects
67
Finally, the
37
49
of obesity that artificially ignore most of the mechanisms by which obesity might reasonably cause PAD. In a few cases, unadjusted models or models adjusted only for age and sex show a significant association with PAD, even though obesity was nonsignificant or protective after multivariable adjustment.
30,49,59
However, in other studies, obesity was found to be either protective or nonsignificant even in unadjusted models or models adjusted only for age and
9,15,36,37,39
sex.
Thus, the failure to find more cases of positive associa­tion between PAD and obesity is not simply an artifact of adjust­ing for factors on the causal pathway in multivariable modeling, but seems to suggest a real lack of consistent evidence that such a relationship exists at all.
Unaccounted for in the multivariable analyses just cited is pos­sible residual confounding by cigarette smoking, which is strongly associated with both PAD and lower BMI. In addition, chronic ill­ness in older persons, including PAD, may lead to weight loss and allow for a spurious inverse correlation between obesity and PAD.
As in coronary heart disease (CHD) epidemiology, there is some evidence to suggest that central adiposity, rather than obesity per se, may be more closely related to an increased risk of PAD. Vogt et al. found that after adjustment for BMI, higher waist/hip ratio was associated with significantly higher risk of PAD.6 In a group of patients with diabetes, it was shown that waist/hip ratio, but not BMI or body fat percentage, was associated with PAD.
53
Alcohol Consumption
68
but not women in the Edinburgh Artery Study, but this association disappeared after adjustment for social class.
9,30
However, in a later analysis of data from one of
Conversely, a protective effect of alcohol was seen in men
69
In Native Americans, a protective effect of alcohol was seen in multivariable analysis, but in elderly Japanese American men, alcohol intake was found to increase rather than decrease the risk of incident PAD.36 Data from the Physician's Health Study suggest that a protective effect related to moderate alcohol consumption may exist.
71
In that study, there was no univariate association between alcohol and claudication incidence, but adjustment for cigarette smoking “unmasked” a significant pro­tective association, reflecting the positive correlation of alcohol con­sumption with smoking, a strong risk factor for PAD. Based on this, it seems possible that incomplete adjustment for smoking in other stud­ies might allow residual confounding that could obscure any protec­tive effect of alcohol, despite multivariable adjustment.
Race and Ethnicity
Data on the association of race with PAD are limited because many large studies of PAD have been conducted in non-Hispanic white groups. A 2003 review of ethnicity and PAD concluded that there were “no large population-based studies assessing the prevalence of PAD in non-Caucasians.”
Several studies suggest a higher risk of PAD among blacks. The CHS, a study of 5084 Medicare beneficiaries in the United States, found that nonwhite (mostly black) race was associated with an odds ratio of 2.12 for PAD after adjustment for traditional risk factors. A study of 933 women aged 65 and older found a higher percentage of black subjects among the PAD (36.3%) versus non-PAD (24.8%)
17
groups.
In the ARIC Study, Zheng et al. found that PAD prevalence
was higher in African Americans than whites in both men (3.3% vs.
2.3%) and women (4.0% vs. 3.3%). able odds ratio of 1.67 for blacks versus non-Hispanic whites.51 The SDPS reported an odds ratio of 2.34 for blacks versus non-Hispanic whites after adjustment for hypertension and diabetes, tional analyses also showed no evidence of a greater sensitivity of blacks to traditional cardiovascular disease risk factors. Finally, a
72
44
The MESA reported a multivari-
52
and addi-
217
CH 16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
70
15
218
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
synthesis of three studies addressing this question reported odds ratios of 2.3 to 3.1 for blacks versus non-Hispanic whites adjusted for age and gender; odds ratios of 1.7 to 2.9 after adjustment for traditional risk factors; and odds ratios of 1.5 to 2.0 after further adjustment for novel risk factors including inflammatory risk fac-
73
tors.
CH
16
Thus, this association is in part explained by traditional risk factors and in part by novel risk factors, but there is an unexplained residual difference. Interestingly, hospital-based studies suggest that anatomical distribution of disease may differ in blacks, with a higher percentage of distal disease in black subjects, even after adjustment for diabetes and other cardiovascular risk factors.
72
Data on other races and ethnic groups are limited. In a study in Honolulu, Hawaii, Asians were reported to have lower PAD prev­alence than comparable non-Hispanic white subjects. MESA and the SDPS data suggest somewhat lower rates of PAD in Asians and Hispanics than in non-Hispanic whites. Native Americans suggested PAD prevalence comparable with that in non-Hispanic whites.
70
51,52
Homocysteine
The association of homocysteine with PAD has been examined in a number of studies, with conflicting results. A 1995 meta-analysis of early case-control studies conducted in the late 1980s and early 1990s suggested an odds ratio of 6.8 for a 5 μmol/L difference in fasting total homocysteine (tHcy).
74
To put this in perspective, the differences between the 25th and 75th percentiles of tHcy among controls in the Physician's Health Study and a study of women in the Netherlands were between 3.5 and 4.0 μmol/L.
60,75
difference noted is therefore not unreasonable as the difference between low and high tHcy levels in the population. In that light, an odds ratio of 6.8 might make homocysteine the single most powerful risk factor for PAD. Interestingly, the odds ratio for PAD in the meta-analysis was strikingly higher than the odds ratios for coronary artery disease (CAD) and cerebrovascular disease, which were below 2 in the same study.
However, more recent studies have produced much lower and frequently nonsignificant estimates of the PAD risk associated with homocysteine. In a large European case-control study, Graham et al. estimated an odds ratio of 1.7 for subjects in the top quintile of homo­cysteine for their control group versus all other subjects—a result of only borderline statistical significance.
76
One population-based study from the Netherlands found a 1.44 odds ratio for a 5 μmol/L difference in fasting tHcy, based on an extreme definition of PAD involving surgery or an ABI of less than 0.5.
77
However, an analysis of a subset of the Rotterdam Study cohort found no significant rela­tionship between tHcy and PAD, based either on the conventional
0.9 ABI cut-off or on a 0.7 ABI cut-off for severe disease. reported a significant association for homocysteine after multivari­able adjustment for traditional risk factors, but the association just missed significance after adjustment for other novel risk factors. nested case-control study using the Physician's Health Study cohort failed to find any association between quartiles of fasting tHcy and claudication. Netherlands also failed to find any significant association between fasting homocysteine and symptomatic PAD.
60
A recent case-control study of young women in the
75
Among patients with PAD, disease progression based on ABI was not significantly different in patients with the highest and lowest 20% of homocysteine levels.
At this point, although it is still possible that homocysteine may be an independent risk factor for PAD, it appears that the early results summarized in the 1995 meta-analysis may have overstated the importance of homocysteine. This may be related to the quality of the studies included in the meta-analysis, which included pri­marily small case-control studies.
74
C-Reactive Protein and Fibrinogen
C-reactive protein (CRP) and fibrinogen are two inflammatory mark­ers that have been shown to be associated with PAD in a number of studies. In an analysis from the Physician's Health Study, each was found to be significantly associated with PAD in multivariable
36
Both the
A study of
The 5 μmol/L
9
The MESA
51
A
models, with odds ratios for the upper versus lower population quartiles of 2.2 for fibrinogen and 2.8 for CRP.60 However, adding both variables to risk prediction models did not improve the accu­racy of prediction because they are significantly intercorrelated. Of the index studies, CRP was studied only in the MESA, and it was not significant in multivariable analysis. included in four of the five studies and was significantly associated with PAD in multivariable analysis in three of them. ies have also reported significant and independent associations of PAD with CRP
75
and fibrinogen.
36,78
51
However, fibrinogen was
9,30,51
Other Risk Factors
A variety of other potential risk factors for PAD have been exam­ined. In several studies, various measures of oral health have been shown to be independently associated with PAD, possibly based on common inflammatory pathways.
79
A study in young women found that self-reported history of various types of infectious dis­eases, such as chicken pox, shingles, mumps, pneumonia, chronic bronchitis, or peptic ulcer, was independently and significantly related to PAD. associated with PAD as diagnosed by ABI.
Psychosocial factors were found to be associated with PAD in
one large cohort in Scotland,
75
Another study found that a history of arthritis was
80
whereas in a large study of Israeli
6
men, anxiety, job-related stress, and manner of coping with job­related conflicts were all significantly related to incident claudi­cation even after adjustment for traditional risk factors. patients with PAD, depressive symptoms were found to be associ­ated with poorer lower-extremity functioning.
81
Genetic factors appear to have a role in PAD, but data are limited. In a study of fraternal and identical twins, Carmelli et al. estimated that 48% of the variability in ABI could be explained by additive genetic effects.
82
It has also been shown that familial hypercholester-
olemia, a genetic disorder, is related to a higher prevalence of PAD.
Other possible risk factors for which some supporting data exist include antiphospholipid antibodies, sedentary lifestyle.
87
Possible protective effects have been reported for hormone replacement therapy, Initiative randomized clinical trial of combined estrogen/progestin therapy showed no effect on the incidence of PAD.
84,85
hypothyroidism,86 and
88
but the Women's Health
89
Interaction and Risk Factor Comparisons
Some research has been conducted into potential variations in the significance and strength of various risk factors as they are estimated in different subgroups and for different PAD-related outcomes.
Differences in the relative strength and significance of risk fac­tors in men and women have been examined in several studies. Many of these studies have concluded that risk factors do not differ substantially in men and women. In the Rotterdam Study, separate models for men and women were compared and failed to reveal differences in risk factors for PAD. Framingham Offspring cohorts, testing for statistical interactions between sex and risk factors failed to provide any evidence of such interactions. States (age 65 and older) found similar risk factor associations with
78
30,50
One study of Medicare beneficiaries in the United
ABI in men and in women, the exceptions being total and LDL cho­lesterol levels, which were related to ABI in women but not in men.
Meijer et al. looked at whether severe PAD, diagnosed based on ABI of less than 0.7, had different risk factors than ABI diagnosed based on the traditional cut-point of 0.9. direction and magnitude of odds ratios were similar for most risk factors under the two criteria. Point estimates suggested that age and current smoking were greater risk factors for conventionally defined PAD, whereas diabetes was more important for severe PAD; however, the 95% CIs overlapped in all cases.
Many risk factors that have been studied for their relationship to PAD were originally identified as risk factors for ischemic heart dis­ease. In the most formal comparison of the relative significance and
9
In the large Framingham and
9
In their analysis, the
Other stud-
1
Among
83
15
strength of risk factors for PAD versus ischemic heart disease, the same risk factors were analyzed for their association with the two diseases in the Edinburgh Artery Study cohort.
49
In that study, only the association with smoking was significantly different for PAD versus ischemic heart disease, with a higher association with PAD. Especially strong or consistent relationships to PAD that were sug­gested for triglycerides and homocysteine were generally not borne out in later studies, as described earlier. In general among risk fac­tors, only smoking and possibly more severe diabetes seem to show stronger associations with PAD than with ischemic heart disease.
Progression of Peripheral Artery Disease
Little is known about the early natural history of PAD, particularly the progression from asymptomatic to early symptomatic disease. Average annual change in ABI has been estimated as 0.01 and 0.02 in various groups,
90,91
but these figures may be somewhat mislead­ing because an average change in ABI masks a variety of changes of different directions and magnitudes.
A more meaningful approach may be to look at the percent­age of the population achieving some categorically defined mea­sure of change. The CHS, a population-based study, found that over 6 years of follow-up, 9.5% of persons showed incident PAD, defined as an ABI drop of more than 0.15 to a level of 0.9 or lower.92 Nicoloff et al. found that in 5 years, 37% of patients experienced a signifi­cant (0.15) worsening of ABI, whereas 22% of patients experi­enced clinical progression of PAD based on a change in symptoms or a need for surgical intervention.
93
Among 415 English smokers with PAD referred for a surgical opinion, about half experienced a significant (
0.14) drop in ABI over the following 48 months.63 In
a group of German PAD patients, PAD was reported to progress in
18.6% of patients during an average follow-up of 64 months, based on a variety of criteria including change in ABI.94 Bird et al. defined a ranked series of six categories of PAD defined based on ABI and other tests; in a study of patients referred to a vascular laboratory,
30.2% of limbs progressed to a more serious category of PAD over an average follow-up time of 4.6 years, but 22.8% of limbs regressed to a less severe category during the same period.
In a study based on angiography, 9.1% of patients annually were found to have evidence of progression of PAD. development of rest pain or gangrene as the criteria for PAD pro­gression, PAD progressed in 2.5% of patients annually.
90
95
In a study using
87
In the latter study, it was noted that PAD progressed at a rate approximately three times greater in the first year following diagnosis than in subsequent
96
years.
Because many studies of PAD progression have used subjects whose recruitment is linked to the referral for diagnostic testing, esti­mates of progression from such studies may be appropriate only for newly diagnosed populations, particularly if follow-up time is short.
Data on risk factors associated with progression of PAD are relatively sparse. In the CHS, significant independent predictors of decline were age, cigarette smoking, diabetes, and dyslipidemia.
92
One report showed age, diabetes, classic claudication, previous intervention, and PAD in the contralateral leg to be independently predictive of PAD progression.
90
One study of English smokers with PAD identified hypertriglyceride­mia as the most important independent risk factor for progression of PAD and onset of critical ischemia. been shown to be associated with an increased risk of need for vas­cular intervention.
97
Patients with premature PAD (onset of symptoms at or before age 45) appear to have more rapid progression of disease and generally poorer outcomes.
63
Hemorheological factors have
98–102
Recent data suggest that while PAD prog ressi on in large arteries was related to smoking, the TC/HDL-C ratio, lipoprotein(a) (lp[a]), and high-sensitivity CRP assay (hs-CRP), only diabetes was associated with progression in smaller arteries.
103
Co-Prevalence of Peripheral Artery Disease and Other Atherosclerotic Disease
Given the common risk factors for PAD and other cardiovascular and cerebrovascular diseases, it is not surprising that cross-section­ally, people with PAD are more likely to have these other disorders,
and vice versa. Among 5084 Medicare beneficiaries in the CHS, prevalence of history of MI was 2.5 times as high in subjects with PAD (based on ABI < 0.9) than those without. For angina, congestive heart failure (CHF), stroke, and transient ischemic attack (TIA), the prevalences were 1.9, 3.3, 3.1, and 2.3 times as high, respectively.
15
Conversely, prevalence of PAD was 2.1 times as high in patients with a history of MI than in those without. Corresponding ratios for angina, CHF, stroke, and TIA were 1.7, 2.6, 2.4, and 2.1, respec-
15
tively.
Other studies have found similar cross-sectional correla-
44,104,105
tions. elevated prevalence of carotid artery stenosis, but significant correlation between severities of the two diseases has been demonstrated.
Subjects with PAD have also been shown to have an
108
106,107
and a modest
Peripheral Artery Disease as a Predictor of Mortality and Morbidity
Going beyond the cross-sectional associations discussed earlier, it has been shown that PAD is prospectively related to morbidity or mortality from other types of atherosclerotic disease, even after adjustment for known common risk factors. Although PAD seems unlikely to directly cause these other diseases, presence of PAD may serve as a marker for underlying atherosclerotic processes or susceptibilities affecting other vascular beds. These prospective relationships are clinically important to the extent that PAD has prognostic value independent of other known risk factors.
Attempts to elucidate this association epidemiologically began with studies of patients having symptomatic PAD in the form of intermittent claudication. Elevated mortality rates among subjects with claudication were reported in the 1970s and 1980s in the Framingham cohort, although this excess risk was markedly atten­uated when subjects with baseline cerebrovascular and CHD were excluded. association between claudication and total or cardiovascular mor­tality in men after adjustment for cardiovascular risk factors and baseline cardiovascular disease. increased mortality risk among claudicants but did not fully adjust for the conventional cardiovascular risk factors. a large and methodologically rigorous study, data from the 18,403 men in the Whitehall cohort were used to show that after adjust­ing for cardiovascular risk factors, claudication was a significant predictor of cardiovascular disease mortality even after excluding subjects with baseline disease.
permitted further investigation into the association between PAD and cardiovascular disease. In 1985, it was first demonstrated that a combination of noninvasive measures, including ABI, were pro­spectively related to all-cause mortality even after adjustment for cardiovascular risk factors and exclusion of subjects with baseline cardiovascular disease. range of 4 to 5; a later reanalysis of the same cohort with addi­tional mortality follow-up demonstrated elevated relative risks for cardiovascular disease and CHD in particular, with no significant increase in noncardiovascular death.
disease are less conclusive. A 1991 study showed a strong association between multiple noninvasive measures of PAD and cerebrovascular
37,109,110
Similarly, a 1982 Finnish study failed to find an
111
Other studies demonstrated
38,95,112
However, in
113
Development of the ABI and other noninvasive measures of PAD
114
Relative risks in this study were in the
3
In the 1990s, a number of other prospective studies confirmed
28,115
116
elderly women,
118
16
and the CHS cohort.29 Most of these stud-
the Edinburgh Artery Study
29
117
an employ-
Data regarding the association of PAD with cerebrovascular
219
CH 16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
220
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
disease morbidity and mortality, with risk ratios of 3.3 for men and
9.0 for women after multivariable adjustment.
119
Data from the Edinburgh Artery Study also showed such an association based on ABI, although after multivariable adjustment, the association persisted for nonfatal but not fatal stroke. CHS failed to show a relationship between low ABI and incident
CH
16
29
stroke.
Another large study, the ARIC Study, showed a significant association between ABI as a continuous variable and ischemic stroke after multivariable adjustment, but failed to show such asso­ciation when ABI was categorized based on a 0.8 cut-point.
Population studies suggest a high ABI (>1.4), is also associated with elevated risk of cardiovascular disease. caused by stiff, often calcified, ankle arteries that may mask under­lying PAD.
14
Recently, the MESA reported that both “low” (<1.00)
16
However, data from the
120
32
Such high ABIs are
TABLE 16-5 Peripheral Artery Disease as a Predictor of Coronary Heart and Cerebrovascular Disease Morbidity and Mortality
95% CI
STUDY
Total Mortality
Criqui, 1992 Large-vessel PAD 3.10 1.80 5.30 Adjusted for conventional risk factors; excludes subjects with
Newman, 1993 ABI < 0.9 3.40 1.60 7.10 Adjusted for conventional risk factors; excludes subjects with
Vogt, 1993 ABI < 0.9 3.10 1.50 6.70 Adjusted for conventional risk factors; excludes subjects with
Kornitzer, 1995 ABI < 0.9 2.07 0.90 4.77 Adjusted for conventional risk factors other than blood
Jager, 1999 ABI < 0.9 1.50 0.79 2.84 Adjusted for conventional risk factors Newman, 1999 ABI < 0.9 1.62 1.24 2.12 Adjusted for conventional risk factors; excludes subjects with
Hooi, 2002 ABI < 0.7 (vs. > 0.95) 2.10 1.60 2.80 Adjusted for conventional risk factors
Cardiovascular Disease Mortality
Criqui, 1992 Large-vessel PAD 6.30 2.60 15.00 Adjusted for conventional risk factors; excludes subjects with
Vogt, 1993 ABI < 0.9 4.50 1.50 6.70 Adjusted for conventional risk factors; excludes subjects with
Kornitzer, 1995 ABI < 0.9 3.29 1.02 10.57 Adjusted for conventional risk factors other than blood
Jager, 1999 ABI < 0.9 2.36 0.92 6.09 Adjusted for conventional risk factors Newman, 1999 ABI < 0.9 2.03 1.22 3.37 Adjusted for conventional risk factors; excludes subjects with
Hooi, 2002 ABI < 0.7 (vs. > 0.95) 2.30 1.70 3.10 Adjusted for conventional risk factors
Coronary Heart Disease Mortality
Criqui, 1992 Large-vessel PAD 4.30 1.40 12.80 Adjusted for conventional risk factors; excludes subjects with
Kornitzer, 1995 ABI < 0.9 3.63 1.11 11.84
Cardiovascular Morbidity
Newman, 1993 ABI < 0.9 2.10 1.10 4.10 Adjusted for conventional risk factors Hooi, 2002 ABI < 0.7 (vs. > 0.95) 1.70 1.30 2.40 Adjusted for conventional risk factors
Myocardial Infarction
Newman, 1999 ABI < 0.9 1.40 0.90 2.17 Adjusted for conventional risk factors; excludes subjects with
Stroke
Newman, 1999 ABI < 0.9 1.12 0.74 1.70 Adjusted for conventional risk factors; excludes subjects with
All Coronary Heart Disease Morbidity and Mortality
Criqui, 2010 ABI <1.0 1.87 1.30 2.68 Adjusted for conventional risk factors; excludes subjects with
All Stroke Morbidity and Mortality
Criqui, 2010 ABI < 1.0 1.56 0.92 2.96 Adjusted for conventional risk factors; excludes subjects with
ABI, ankle-brachial index; CHD, coronary heart disease; MI, myocardial infarction; PAD, peripheral artery disease.
PERIPHERAL ARTERY
DISEASE MEASUREMENT
ABI >1.4 2.15 1.09 4.24
ABI > 1.4 2.69 0.97 7.55
HAZARD
RATIO LOWER UPPER
and “high” (>1.40) ABI were associated with increased risk of inci­dent cardiovascular disease events, even after adjustment for tra­ditional and novel risk factors.
121
Interestingly, high ABI showed a stronger association for stroke than low ABI. Also, this was the first report to show that the ABI predicted events independent of other measures of extant atherosclerosis—specifically, coronary artery calcium, carotid intima media thickness, and major electrocardio­graphic abnormalities. Recent evidence also indicates that inde­pendent of baseline ABI, a more rapid deterioration in ABI carries a worse prognosis.
122
Table 16-5 provides a summary of studies of the association of
PAD with various mortality and morbidity outcomes. The table is limited to studies using a noninvasive measure of PAD (usually ABI at various cut-points), and logistic or proportional hazards
MODEL SPECIFICATIONS
baseline angina, MI, stroke (multiple criteria)
baseline cardiovascular disease
baseline cardiovascular disease
pressure; excludes baseline CHD
baseline cardiovascular disease
baseline angina, MI, stroke (multiple criteria)
baseline cardiovascular disease
pressure; excludes baseline CHD
baseline cardiovascular disease
baseline angina, MI, stroke (multiple criteria)
Adjusted for conventional risk factors other than blood
pressure; excludes baseline CHD
baseline cardiovascular disease
baseline cardiovascular disease
baseline cardiovascular disease
baseline cardiovascular disease
regression models with multivariable adjustment for conventional cardiovascular risk factors. Results are shown with multivariable adjustment and after exclusion of subjects with baseline cardiovas­cular disease, where such exclusion was attempted.
Summary and Conclusions
Peripheral artery disease is atherosclerotic obstruction of the arteries of the lower extremities. The most common symptom of PAD is intermittent claudication, which is pain in the legs associ­ated with walking that is relieved by rest. However, noninvasive measures such as the ABI show that asymptomatic PAD is sev­eral times more common in the population than intermittent claudication. Peripheral artery disease prevalence is sharply age related, rising to more than 10% among patients in their 60s and 70s. Prevalence appears to be higher among men than women for moderate to severe disease. Major risk factors for PAD are simi­lar to those for cardiovascular and cerebrovascular disease, with some differences in the relative importance of factors. Smoking is a particularly strong risk factor for PAD, as is diabetes. Peripheral artery disease is cross-sectionally associated with cardiovascular and cerebrovascular disease. After adjustment for known cardio­vascular disease risk factors, PAD is associated with an increased risk of cardiovascular and cerebrovascular disease, morbidity, and mortality.
With general aging of the population, it seems likely that PAD will be increasingly common in the future. Diagnosis and treatment of PAD in its asymptomatic stage may prove highly beneficial, particu­larly with respect to interventions aimed at ameliorating risk factors common to atherosclerotic disease of the several vascular beds.
REFERENCES
1. Bowlin SJ, Medalie JH, Flocke SA, et al: Epidemiology of intermittent claudication in
middle-aged men, Am J Epidemiol 140:418, 1994.
2. Allison MA, Ho E, Denenberg JO, et al: Ethnic-specific prevalence of peripheral arterial
disease in the United States, Am J Prev Med 32:328, 2007.
3. Criqui MH, Langer RD, Fronek A, et al: Mortality over a period of 10 years in patients with
peripheral arterial disease, N Engl J Med 326:381, 1992.
4. Rose GA: The diagnosis of ischaemic heart pain and intermittent claudication in field
surveys, Bull World Health Organ 27:645, 1962.
5. Criqui MH, Denenberg JO, Bird CE, et al: The correlation between symptoms and non-invasive
test results in patients referred for peripheral arterial disease testing, Vasc Med 1:65, 1996.
6. Vogt MT, Cauley JA, Kuller LH, et al: Prevalence and correlates of lower-extremity arterial
disease in elderly women, Am J Epidemiol 137:559, 1993.
7. Winsor T: Influence of arterial disease on the systolic blood pressure gradients of the
extremity, Am J Med Sci 220:117, 1950.
8. Hooi JD, Stoffers HE, Kester AD, et al: Peripheral arterial occlusive disease: prognostic value
of signs, symptoms, and the ankle-brachial pressure index, Med Decis Making 22:99, 2002.
9. Meijer W T, Grobbee DE, Hunink MG, et al: Determinants of peripheral arterial disease in
the elderly: the Rotterdam study, Arch Intern Med 160:2934, 2000.
10. Meijer W T, Hoes AW, Rutgers D, et al: Peripheral arterial disease in the elderly: the
Rotterdam Study, Arterioscler Thromb Vasc Biol 18:185, 1998.
11. Yao ST, Hobbs JT, Irvine WT: Ankle systolic pressure measurements in arterial disease
affecting the lower extremities, Br J Surg 56:676, 1969.
12. Ouriel K, McDonnell AE, Metz CE, et al: Critical evaluation of stress testing in the diagnosis
of peripheral vascular disease, Surgery 91:686, 1982.
13. Lijmer JG, Hunink MG, van den Dungen JJ, et al: ROC analysis of noninvasive tests for
peripheral arterial disease, J Ultrasound Med Biol 22:391, 1996.
14. Aboyans V, Ho E, Denenberg JO, et al: The association between elevated ankle systolic
pressures and peripheral occlusive arterial disease in diabetic and non-diabetic subjects, J Vasc Surg 48:1197, 2008.
15. Newman AB, Siscovick DS, Manolio TA, et al: Ank le-arm index as a marker of atherosclerosis
in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group, Circulation 88:837, 1993.
16. Leng GC, Fowkes FG, Lee AJ, et al: Use of ankle-brachial pressure index to predict
cardiovascular events and death: a cohort study, BMJ 313:1440, 1996.
17. McDermott MM, Fried L, Simonsick E, et al: Asymptomatic peripheral arterial disease
is independently associated with impaired lower extremity functioning: the Women's Health and Aging Study, Circulation 101:1007, 2000.
18. McDermott MM, Liu K, O'Brien E, et al: Measuring physical activity in peripheral arterial
disease: a comparison of two physical activity questionnaires with an accelerometer, Angiology 51:91, 2000.
19. McDermott MM, Ferrucci L, Simonsick EM, et al: The ankle-brachial index and change in
lower-extremity functioning over time: the Women's Health and Aging Study, J A m Geriatr Soc 50:238, 2002.
20. McDermott MM, Criqui MH, Liu K, et al: Lower ankle-brachial index, as calculated by
averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease, J Vasc Surg 32:116, 2000.
21. Aboyans V, Lacroix P, Lebourdon A, et al: The intra- and interobserver variability of ankle-arm blood pressure index according to its mode of calculation, J Clin Epidemiol 56:215, 2003.
22. Shadman R, Criqui MH, Bundens WP, et al: Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases, J Am Coll Cardiol 44:618, 2004.
23. Fowkes FG, Housley E, Cawood EH, et al: Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population, Int J Epidemiol 20:384, 1991.
24. Hiatt WR, Hoag S, Hamman RF: Effect of diagnostic criteria on the prevalence of peripheral arterial disease: the San Luis Valley Diabetes Study, Circulation 91:1472, 1995.
25. Aboyans V, Criqui MH, McClelland RL, et al: Intrinsic contribution of gender and ethnicity to normal ankle-brachial index values: the Multi-Ethnic Study of Atherosclerosis (MESA), J Vasc Surg 45:319, 2007.
26. Kreines K, Johnson E, Albrink M, et al: The course of peripheral vascular disease in non­insulin-dependent diabetes, Diabetes Care 8:235, 1985.
27. Orchard TJ, Strandness DE Jr.: Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Heart Association and the American Diabetes Association, 18-20 September 1992, New Orleans, Louisiana, Diabetes Care 16:1199, 1993.
28. McKenna M, Wolfson S, Kuller L: The ratio of ankle and arm arterial pressure as an independent predictor of mortality, Atherosclerosis 87:119, 1991.
29. Newman AB, Shemanski L, Manolio TA, et al: Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group, Arterioscler Thromb Vasc Biol 19:538, 1999.
30. Murabito JM, Evans JC, Nieto K, et al: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study, Am Heart J 143:961, 2002.
31. Wang JC, Criqui MH, Denenberg JO, et al: Exertional leg pain in patients with and without peripheral arterial disease, Circulation 112:3501, 2005.
32. Ankle Brachial Index Collaboration: Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality. A meta-analysis, JAMA 300:197, 2008.
33. Criqui MH, Fronek A, Barrett-Connor E, et al: The prevalence of peripheral arterial disease in a defined population, Circulation 71:510, 1985.
34. Beks PJ, Mackaay AJ, de Neeling JN, et al: Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study, Diabetologia 38:86, 1995.
35. Stoffers HE, Rinkens PE, Kester AD, et al: The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease, Int J Epidemiol 25:282, 1996.
36. Curb JD, Masaki K, Rodriguez BL, et al: Peripheral artery disease and cardiovascular risk factors in the elderly. The Honolulu Heart Program, Arterioscler Thromb Vasc Biol 16:1495, 1996.
37. Kannel WB, McGee DL: Update on some epidemiologic features of intermittent claudication: the Framingham Study, J Am Geriatr Soc 33:13, 1985.
38. Dagenais GR, Maurice S, Robitaille NM, et al: Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study, Clin Invest Med 14:93, 1991.
39. Bainton D, Sweetnam P, Baker I, et al: Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart disease study, Br Heart J 72:128, 1994.
40. Leng GC, Lee AJ, Fowkes FG, et al: Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population, Int J Epidemiol 25:1172, 1996.
41. Ingolfsson IO, Sigurdsson G, Sigvaldason H, et al: A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol—the Reykjavik Study, J Clin Epidemiol 47:1237, 1994.
42. Hooi JD, Kester AD, Stoffers HE, et al: Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study, Am J Epidemiol 153:666, 2001.
43. Gallotta G, Iazzetta N, Milan G, et al: Prevalence of peripheral arterial disease in an elderly rural population of southern Italy, Gerontology 43:289, 1997.
44. Zheng ZJ, Sharrett AR, Chambless LE, et al: Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study, Atherosclerosis 131:115, 1997.
45. McDermott MM, Liu K, Criqui MH, et al: The ankle brachial index and subclinical cardiac and carotid disease: the Multi-Ethnic Study of Atherosclerosis, Am J Epidemiol 162:33, 2005.
46. Faulkner KW, House AK, Castleden WM: The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease, Med J Aust 1:217, 1983.
47. Quick CR, Cotton LT: The measured effect of stopping smoking on intermittent claudication, Br J Surg 69(Suppl):S24, 1982.
48. Jonason T, Bergstrom R: Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality, Acta Med Scand 221:253, 1987.
49. Fowkes FG, Housley E, Riemersma RA, et al: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study, Am J Epidemiol 135:331, 1992.
50. Murabito JM, D'Agostino RB, Silbershatz H, et al: Intermittent claudication: a risk profile from The Framingham Heart Study, Circulation 96:44, 1997.
51. Allison MA, Criqui MH, McClelland RL, et al: the effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA), J Am Coll Cardiol 48:1190, 2006.
52. Criqui MH, Vargas V, Denenberg JO, et al: Ethnicity and peripheral arterial disease: the San Diego Population Study, Circulation 112:2703, 2005.
53. Katsilambros NL, Tsapogas PC, Arvanitis MP, et al: Risk factors for lower extremity arterial disease in non-insulin-dependent diabetic persons, Diabet Med 13:243, 1996.
54. Tseng CH: Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients, Angiology 54:331, 2003.
55. Kallio M, Forsblom C, Groop PH, et al: Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years, Diabetes Care 26:1241, 2003.
56. Jude EB, Oyibo SO, Chalmers N, et al: Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome, Diabetes Care 24:1433, 2001.
221
CH 16
THE EPIDEMIOLOGY OF PERIPHERAL ARTERY DISEASE
222
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
57. Haltmayer M, Mueller T, Horvath W, et al: Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease, Int Angiol 20:200, 2001.
58. Natarajan S, Glick H, Criqui M, et al: Cholesterol measures to identify and treat individuals at risk for coronary disease, Am J Prev Med 25:50, 2003.
59. Ness J, Aronow WS, Ahn C: Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice, J Am Geriatr Soc 48:312, 2000.
60. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a
CH
16
comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease, JAMA 285:2481, 2001.
61. Fowkes FG: Epidemiology of atherosclerotic arterial disease in the lower limbs, Eur J Vasc Surg 2:2831, 1988.
62. Cheng SW, Ting AC, Wong J: Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease, Ann Vasc Surg 11:217, 1997.
63. Smith I, Franks PJ, Greenhalgh RM, et al: The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia, Eur J Vasc Endovasc Surg 11:402, 1996.
64. Mowat BF, Skinner ER, Wilson HM, et al: Alterations in plasma lipids, lipoproteins and high density lipoprotein subfractions in peripheral arterial disease, Atherosclerosis 131:161,
1997.
65. Criqui MH, Denenberg JO, Langer RD, et al: Peripheral arterial disease and hypertension. In Izzo JL, Black HR, editors: Hypertension primer, Dallas, 2003, American Heart Association, 250.
66. Dormandy J, Heeck L, Vig S: Predictors of early disease in the lower limbs, Semin Vasc Surg 12:109, 1999.
67. Tseng CH: Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients, Angiology 54:331, 2003.
68. Vliegenthart R, Geleijnse JM, Hofman A, et al: Alcohol consumption and risk of peripheral arterial disease: the Rotterdam Study, Am J Epidemiol 155:332, 2002.
69. Jepson RG, Fowkes FG, Donnan PT, et al: Alcohol intake as a risk factor for peripheral arterial disease in the general population in the Edinburgh Artery Study, Eur J Epidemiol 11:9, 1995.
70. Fabsitz RR, Sidawy AN, Go O, et al: Prevalence of peripheral arterial disease and associated risk factors in American Indians: the Strong Heart Study, Am J Epidemiol 149:330, 1999.
71. Camargo CA Jr., Stampfer MJ, Glynn RJ, et al: Prospective study of moderate alcohol consumption and risk of peripheral arterial disease in U.S. male physicians, Circulation 95:577, 1997.
72. Hobbs SD, Wilmink AB, Bradbury AW: Ethnicity and peripheral arterial disease, Eur J Vasc Endovasc Surg 25:505, 2003.
73. Ix JH, Allison MA, Denenberg JO, et al: Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study, J Am Coll Cardiol 51:2347, 2008.
74. Boushey CJ, Beresford SA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes, JAMA 274:1049, 1995.
75. Bloemenkamp DG, van den Bosch MA, Mali WP, et al: Novel risk factors for peripheral arterial disease in young women, Am J Med 113:462, 2002.
76. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project, JAMA 277:1775, 1997.
77. Hoogeveen EK, Kostense PJ, Beks PJ, et al: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study, Arterioscler Thromb Vasc Biol 18:133, 1998.
78. Taylor LM Jr., Moneta GL, Sexton GJ, et al: Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease, J Vasc Surg 29:8, 1999.
79. Hung HC, Willett W, Merchant A, et al: Oral health and peripheral arterial disease, Circulation 107:1152, 2003.
80. Whiteman MC, Deary IJ, Fowkes FG: Personality and social predictors of atherosclerotic progression: Edinburgh Artery Study, Psychosom Med 62:703, 2000.
81. McDermott MM, Greenland P, Guralnik JM, et al: Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease, J Gen Intern Med 18:461, 2003.
82. Carmelli D, Fabsitz RR, Swan GE, et al: Contribution of genetic and environmental influences to ankle-brachial blood pressure index in the NHLBI Twin Study. National Heart, Lung, and Blood Institute, Am J Epidemiol 151:452, 2000.
83. Kroon AA, Ajubi N, van Asten WN, et al: The prevalence of peripheral vascular disease in familial hypercholesterolaemia, J Intern Med 238:451, 1995.
84. Taylor LM Jr., Chitwood RW, Dalman RL, et al: Antiphospholipid antibodies in vascular surgery patients: a cross-sectional study, Ann Surg 220:544, 1994.
85. Lam EY, Taylor LM Jr., Landry GJ, et al: Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity bypass operations, J Vasc Surg 33:976, 2001.
86. Mya MM, Aronow WS: Increased prevalence of peripheral arterial disease in older men and women with subclinical hypothyroidism, J Gerontol A Biol Sci Med Sci 58:68, 2003.
87. Asgeirsdottir LP, Agnarsson U, Jonsson GS: Lower extremity blood flow in healthy men: effect of smoking, cholesterol, and physical activity—a Doppler study, Angiology 52:437,
2001.
88. Westendorp IC, in't Veld BA, Grobbee DE, et al: Hormone replacement therapy and peripheral arterial disease: the Rotterdam Study, Arch Intern Med 160:2498, 2000.
89. Hsia J, Criqui MH, Rodabough R, et al: Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative, Circulation 109:620, 2004.
90. Bird CE, Criqui MH, Fronek A, et al: Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing, Vasc Med 4:15, 1999.
91. Fowkes FG, Lowe GD, Housley E, et al: Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease, Lancet 342:84, 1993.
92. Kennedy M, Solomon C, Manolio TA, et al: Risk factors for declining ankle-brachial index in men and women 65 years or older: the Cardiovascular Health Study, Arch Intern Med 165:1896, 2005.
93. Nicoloff AD, Taylor LM Jr., Sexton GJ, et al: Relationship between site of initial symptoms and subsequent progression of disease in a prospective study of atherosclerosis progression in patients receiving long-term treatment for symptomatic peripheral arterial disease, J Vasc Surg 35:38, 2002.
94. Taute BM, Gläser C, Taute R, et al: Progression of atherosclerosis in patients with peripheral arterial disease as a function of angiotensin-converting enzyme gene insertion/deletion polymorphism, Angiology 53:375, 2002.
95. Walsh DB, Gilbertson JJ, Zwolak RM, et al: The natural history of superficial femoral artery stenoses, J Vasc Surg 14:299, 1991.
96. Jelnes R, Gaardsting O, Hougaard Jensen K, et al: Fate in intermittent claudication: outcome and risk factors, Br Med J (Clin Res Ed) 293:1137, 1986.
97. Smith FB, Lowe GD, Lee AJ, et al: Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication, J Vasc Surg 28:129, 1998.
98. McCready RA, Vincent AE, Schwartz RW, et al: Atherosclerosis in the young: a virulent disease, Surgery 96:863, 1984.
99. Pairolero PC, Joyce JW, Skinner CR, et al: Lower limb ischemia in young adults: prognostic implications, J Vasc Surg 1:459, 1984.
100. Hallett JW Jr., Greenwood LH, Robison JG: Lower extremity arterial disease in young adults: a systematic approach to early diagnosis, Ann Surg 202:647, 1985.
101. Valentine RJ, MacGillivray DC, DeNobile JW, et al: Intermittent claudication caused by atherosclerosis in patients aged forty years and younger, Surgery 107:560, 1990.
102. Levy PJ, Hornung CA, Haynes JL, et al: Lower extremity ischemia in adults younger than forty years of age: a community-wide survey of premature atherosclerotic arterial disease, J Vasc Surg 19:873, 1994.
103. Aboyans V, Criqui MH, Denenberg JO, et al: Risk factors for progression of peripheral arterial disease in large and small vessels, Circulation 113:2623, 2006.
104. Criqui MH, Denenberg JO, Langer RD, et al: The epidemiology of peripheral arterial disease: importance of identifying the population at risk, Vasc Med 2:221, 1997.
105. Ness J, Aronow WS: Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice, J Am Geriatr Soc 47:1255, 1999.
106. Alexandrova NA, Gibson WC, Norris JW, et al: Carotid artery stenosis in peripheral vascular disease, J Vasc Surg 23:645, 1996.
107. Pilcher JM, Danaher J, Khaw KT: The prevalence of asymptomatic carotid artery disease in patients with peripheral vascular disease, Clin Radiol 55:56, 2000.
108. Long TH, Criqui MH, Vasilevskis EE, et al: The correlation between the severity of peripheral arterial disease and carotid occlusive disease, Vasc Med 4:135, 1999.
109. Kannel WB, Skinner JJ Jr., Schwartz MJ, et al: Intermittent claudication: incidence in the Framingham Study, Circulation 41:875, 1970.
110. Kannel WB, Shurtleff D: The natural history of arteriosclerosis obliterans, Cardiovasc Clin 3:37, 1971.
111. Reunanen A, Takkunen H, Aromaa A: Prevalence of intermittent claudication and its effect on mortality, Acta Med Scand 211:249, 1982.
112. Kallero KS: Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography: a ten-year follow-up study, J Chronic Dis 34:455, 1981.
113. Smith GD, Shipley MJ, Rose G: Intermittent claudication, heart disease risk factors, and mortality: the Whitehall Study, Circulation 82:1925, 1990.
114. Criqui MH, Coughlin SS, Fronek A: Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study, Circulation 72:768, 1985.
115. McDermott MM, Feinglass J, Slavensky R, et al: The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease, J Gen Intern Med 9:445, 1994.
116. Newman AB, Sutton-Tyrrell K, Vogt MT, et al: Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index, JAMA 270:487, 1993.
117. Vogt MT, Cauley JA, Newman AB, et al: Decreased ankle/arm blood pressure index and mortality in elderly women, JAMA 270:465, 1993.
118. Kornitzer M, Dramaix M, Sobolski J, et al: Ankle/arm pressure index in asymptomatic middle-aged males: an independent predictor of ten-year coronary heart disease mortality, Angiology 46:211, 1995.
119. Criqui MH, Langer RD, Fronek A, et al: Coronary disease and stroke in patients with large­vessel peripheral arterial disease, Drugs 42(Suppl 5):16, 1991.
120. Tsai AW, Folsom AR, Rosamond WD, et al: Ankle-brachial index and 7-year ischemic stroke incidence: the ARIC study, Stroke 32:1721, 2001.
121. Criqui MH, McClelland RL, McDermott MM, et al: The ankle-brachial index and incident cardiovascular events in the MESA (Multi-Ethnic Study of Atherosclerosis), J Am Coll Cardiol 56:1506, 2010.
122. Criqui MH, Ninomiya JK, Wingard DL, et al: Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality, J Am Coll Cardiol 52:1736, 2008.